Jung Hana, Shin Da Wit, Cheung Dae Young, Lee Han Hee, Kim Jin Il, Park Soo-Heon, Kim Tae Jung
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Korean J Gastroenterol. 2023 Jan 25;81(1):29-35. doi: 10.4166/kjg.2022.129.
BACKGROUND/AIMS: The gastric extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (gastric MALT lymphoma) are mostly related to infections. However, chromosomal aberration involving translocation t(11;18) is also frequently reported in these patients.
The study was a retrospective review and analysis of electronic medical records to assess the factors which affect complete remission (CR) in patients with gastric MALT lymphoma. Based on the medical records, subjects with gastric MALT lymphoma were enrolled consecutively from January 2004 to December 2021.
Among the 77 subjects who were found with gastric MALT lymphoma in the database, 65 cases with complete records were analyzed. Of these, 66.2% (43/65) were positive. Genetic analyses for t(11:18) were done on 41 subjects. The t(11:18) chromosomal translocation with MALT1:BIRC3 fusion was found in 31.7% (13/41) of the subjects. With eradication therapy, 75% (21/28) of the subjects without t(11:18) achieved CR. However, only 23.1% (3/13) subjects with t(11:18) could achieve CR (p-value= 0.009). In the -positive group, 85.7% (18/21) subjects without t(11:18) achieved CR with eradication therapy, but 71.4% (5/7) subjects with t(11:18) failed to achieve CR (p-value=0.004). In the -negative group, 42.3% (3/7) of the subjects without t(11:18) achieved CR with eradication therapy. However, 83.3% (5/6) of -negative subjects with t(11:18) failed to achieve CR with eradication therapy and needed additional radiotherapy (p-value=0.396).
negativity and the presence of t(11:18) were both risk factors for failure to achieve CR with eradication therapy as the first line of treatment.
背景/目的：胃黏膜相关淋巴组织结外边缘区B细胞淋巴瘤（胃MALT淋巴瘤）大多与感染有关。然而，这些患者中也经常报告涉及t(11;18)易位的染色体畸变。
本研究是一项对电子病历的回顾性审查和分析，以评估影响胃MALT淋巴瘤患者完全缓解（CR）的因素。根据病历，2004年1月至2021年12月连续纳入胃MALT淋巴瘤患者。
在数据库中发现的77例胃MALT淋巴瘤患者中，分析了65例记录完整的病例。其中，66.2%（43/65）为阳性。对41例患者进行了t(11:18)的基因分析。在31.7%（13/41）的患者中发现了伴有MALT1:BIRC3融合的t(11:18)染色体易位。采用根除治疗，无t(11:18)的患者中有75%（21/28）达到CR。然而，有t(11:18)的患者中只有23.1%（3/13）能够达到CR（p值=0.009）。在阳性组中，无t(11:18)的患者中有85.7%（18/21）通过根除治疗达到CR，但有t(11:18)的患者中有71.4%（5/7）未能达到CR（p值=0.004）。在阴性组中，无t(11:18) 的患者中有42.3%（3/7）通过根除治疗达到CR。然而，有t(11:18)的阴性患者中有83.3%（5/6）通过根除治疗未能达到CR，需要额外的放疗（p值=0.396）。
阴性和存在t(11:18)都是以根除治疗作为一线治疗未能达到CR的危险因素。
